Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Matching placebo
Drug: Aprocitentan 25 mg
Drug: Aprocitentan 100 mg
Other: Moxifloxacin control to establish assay sensitivity

First Posted Date: 2020-02-24

Last Posted Date: 2022-11-23

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 48

Registration Number: NCT04281342

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Combined oral contraceptives (COC)
Drug: Moxifloxacin 400mg
Drug: Matching Placebo
Drug: Cenerimod 0.5 mg
Other: Charcoal, activated
Drug: Cenerimod 4 mg

First Posted Date: 2020-02-05

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 97

Registration Number: NCT04255277

Locations: 🇫🇷
Site 1, Rennes, France

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Subjects

Interventions: Drug: Aprocitentan

First Posted Date: 2020-02-05

Last Posted Date: 2022-11-23

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 17

Registration Number: NCT04252495

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱
Biokinetica S.A., Jozefow, Poland

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Moxifloxacin
Drug: Daridorexant

First Posted Date: 2020-01-31

Last Posted Date: 2020-09-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 36

Registration Number: NCT04250506

Locations: 🇨🇿
CEPHA s.r.o., Pilsen, Czechia

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-1014-6470 (MAD)
Drug: ACT-1014-6470 (SAD)
Drug: Placebo (MAD)
Drug: Placebo (SAD)
Drug: 14C-ACT-1014-6470 microtracer
Drug: 14C-ACT-1014-6470 microtracer placebo

First Posted Date: 2019-12-03

Last Posted Date: 2020-08-12

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 88

Registration Number: NCT04183686

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Phase 3

Withdrawn

Conditions: Hypertension
Renal Insufficiency, Chronic

Interventions: Drug: Aprocitentan 25 mg
Drug: Placebo

First Posted Date: 2019-11-14

Last Posted Date: 2022-11-23

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Registration Number: NCT04162366

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ACT-709478

First Posted Date: 2019-10-10

Last Posted Date: 2020-02-25

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 20

Registration Number: NCT04123288

Locations: 🇨🇿
CEPHA s.r.o., Pilsen, Czechia

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Matching Placebo
Drug: Cenerimod

First Posted Date: 2019-08-09

Last Posted Date: 2020-04-27

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 20

Registration Number: NCT04052360

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Phase 1

Completed

Conditions: Renal Insufficiency
Healthy

Interventions: Drug: ACT-541468

First Posted Date: 2019-07-18

Last Posted Date: 2020-09-03

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 16

Registration Number: NCT04024332

Locations: 🇩🇪
APEX GmbH, München, Germany

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: ID-085

First Posted Date: 2019-04-12

Last Posted Date: 2019-11-22

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 32

Registration Number: NCT03913000

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy